Results 111 to 120 of about 15,200 (191)

Infection risks associated with daratumumab-containing regimens in multiple myeloma: a systematic review and meta-analysis. [PDF]

Front Oncol
Huang ZY, Liu XL, Li T, Luo CH.
europepmc   +1 more source

Resolving the Interference of Anti-CD38 Antibodies on Blood Compatibility Assays Using CD38 "Baitbodies" Approach. [PDF]

J Immunol Res
Gnann DC, Steinke S, Garritsen HSP, Hust M.   +3 more
europepmc   +1 more source

Emerging therapeutics for the treatment of light chain and transthyretin amyloidosis [PDF]

, 2019
Lenihan, Daniel J, Stockerl-Goldstein, Keith E, Zhang, Kathleen W   +2 more
core   +1 more source

Safety and efficacy of daratumumab in immune thrombocytopenia. [PDF]

Blood Adv
Tsykunova G, Holme PA, Tran HTT, Frederiksen H, Tjønnfjord E, Munthe LA, Drivet E, Kared H, Sørvoll IH, Ahlen MT, Mahévas M, Michel M, Bussel J, Kuter DJ, Anderson Tvedt TH, Ghanima W.   +15 more
europepmc   +1 more source

Acute Rejection With DSA-Negative Severe Microvascular Inflammation in a Kidney Transplant Recipient With an Isolated DPB1*04-Mismatch Successfully Stabilised With Daratumumab. [PDF]

HLA
Knödl L, Büttner-Herold M, Götz M, Luber M, Spriewald B, Oellerich M, Beck J, Banas B, Zecher D.   +8 more
europepmc   +1 more source

Natural Killer Cells in Cancer Immunotherapy [PDF]

, 2019
Arndt MA, Chester C, Cortez VS, D'Andrea A, Elsasser D, Ferrini S, Gao Y, Hartmann F, Lotze MT, Miller JS, Orr MT, Seillet C, Soiffer RJ, Soto EO, Weiner LM, Yron I   +15 more
core   +1 more source

Clinical significance of t(11;14) translocation in systemic AL amyloidosis in the era of daratumumab therapy. [PDF]

Clin Exp Med
Nishimura N, Kawano Y, Yasunaga JI.
europepmc   +1 more source

Graves-PCD: protocol for a randomised, dose-finding, adaptive trial of the plasma cell-depleting agent daratumumab in severe Graves\u27 disease [PDF]

\ua9 Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY. Published by BMJ. INTRODUCTION: Severe Graves\u27 disease is a life-changing condition with poor outcomes from currently available treatments.
Bibby I, Bradley P, Cole M, Grixti L, Maier RH, McGregor N, Pearce SH, Walker J, Wason J, Wolstenhulme F   +9 more
core  

Evaluation of the reporting quality of randomized controlled trials for treatments in multiple myeloma published the last 5 years using the CONSORT 2010 statment [PDF]

, 2016
Ντέλλας, Παναγιώτης
core   +1 more source

Daratumumab combined with anti-CD20 therapy in pediatric and adult refractory idiopathic nephrotic syndrome: single-center experience. [PDF]

Front Immunol
Naciri Bennani H, Sandaye T, Charroyer Q, Etangsale A, Vacher Coponat H, Julien M, Mear V, Dunand O, Di Ascia L.   +8 more
europepmc   +1 more source